Head-to-head · WeighScore
Gala Health vs Pallas Health
By GLP-1 ScorecardUpdated
Score comparison
Gala Health has the higher recorded score — 82.9/100 to 69.3/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
Before you choose
Before comparing the headline prices, the Gala Health review and the Pallas Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Gala Health vs Peptivo and Get Thin MD vs Pallas Health compare each of them with another graded program, and the list of alternatives to Gala Health ranks the programs closest to Gala Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Gala Health | Pallas Health |
|---|---|---|
| WeighScore | 82.9/100 | 69.3/100 |
| Grade | B− | C |
| Site position | #11 | #142 |
| Semaglutide | From $69/mo on the annual plan, billed once a year (campaign shows $129/mo; offers conflict—confirm billing term) | $139 first period, then $199 every four weeks (compounded; confirm selected quote) |
| Tirzepatide | From $99/mo on the annual plan, billed once a year (campaign shows $179/mo; offers conflict—confirm term) | $179 first period, then $299 every four weeks (compounded; confirm selected quote) |
| Coverage | Coverage wording differs: all 50 on homepage, most U.S. states in campaign | Confirm treatment and visit requirements for your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Campaign advertises $129 semaglutide and $179 tirzepatide with medication and telehealth visits included if prescribed
- Brand-name Ozempic path and broader menopause/HRT services listed
- Terms identify clinical practice networks; actual clinician and pharmacy assignment still need checking
What to consider
- Annual-plan and no-contract campaign presentations differ; the lowest prices are advertised as billed once a year
- Cancel at least 72 hours before renewal; ordinary cancellation does not produce a refund
- Medical-disqualification refund wording differs between full-refund and remaining/current-cycle provisions
- Dispensing pharmacy not identified for an individual order; oral option is a waitlist, not a current offer
Strengths
- Publishes first-period and four-week renewal amounts
- Explains when the charge is triggered and how to cancel future renewal
- Terms link to a pharmacy partner directory
What to consider
- Annual monthly equivalents do not establish the selected debit
- Once prescribed, the current cycle ordinarily is not prorated or refunded
- The six-month promise has separate eligibility and timing requirements
Featured provider
Gala Health
Factor scores not reassessed.Gala Health scores 82.9/100 (B−). Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.